Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes

Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes

Antipsychotic-induced movement disorders are major side effects of antipsychotic drugs among schizophrenia patients, and include antipsychotic-induced parkinsonism (AIP) and tardive dyskinesia (TD). Substantial pharmacogenetic work has been done in this field, and several susceptibility variants hav...

Full description

Bibliographic Details
Main Authors:	Lior eGreenbaum, Bernard eLerer
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2015-02-01
Series:	Frontiers in Neurology
Subjects:	Schizophrenia Parkinson's disease Tardive dyskinesia Antipsychotic induced parkinsonism L-dopa induced dyskinesia.
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fneur.2015.00027/full

Similar Items

Candidate genes involved in the development of antipsychotic-induced tardive dyskinesia in patients with schizophrenia
by: E. E. Vaiman, et al.
Published: (2020-12-01)

Pathophysiological mechanisms underlying antipsychotic-induced tardive dyskinesia
by: E. E. Vayman, et al.
Published: (2020-01-01)

Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients
by: Elena E. Vaiman, et al.
Published: (2021-07-01)

Probable respiratory dyskinesia in an elderly patient after sudden stoppage of antipsychotics
by: Vikram Vaidya, et al.
Published: (2016-01-01)

CLINICAL AND SOCIAL RISK FACTORS OF TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA DURING ANTIPSYCHOTIC TREATMENT
by: Ye. G. Kornetova, et al.
Published: (2015-02-01)

Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia
by: Stanley N. Caroff, et al.
Published: (2018-09-01)

Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease
by: Eunju Shin, et al.
Published: (2012-09-01)

Abnormal cortical facilitation and L-dopa-induced dyskinesia in Parkinson's disease
by: Andrea Guerra, et al.
Published: (2019-11-01)

Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease
by: Felipe Patricio, et al.
Published: (2020-12-01)

Drug-induced tardive dyskinesia
by: T. M. Ostroumova, et al.
Published: (2020-02-01)

Tardive dyskinesia on clozapine: A case report
by: Laila Asmal
Published: (2009-03-01)

Advances in non-dopaminergic pharmacological treatments of Parkinson's disease
by: Sandy eStayte, et al.
Published: (2014-05-01)

Pharmacogenetics of drug-induced dyskinesias in Parkinson's disease
by: A. A. Tappakhov, et al.
Published: (2020-02-01)

Interaction between the 5-HT system and the basal ganglia: Functional implication and therapeutic perspective in Parkinson’s disease
by: Cristina eMiguelez, et al.
Published: (2014-03-01)

Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats
by: Fernanda Fiel Peres, et al.
Published: (2016-09-01)

Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia
by: Mathieu Bourdenx, et al.
Published: (2014-02-01)

Severe tardive dystonia on low dose short duration exposure to atypical antipsychotics: Factors explored
by: Nilanjan C Chandra, et al.
Published: (2017-01-01)

Antipsychotic-induced tardive dyskinesia as a serious adverse effect in the psychopharmacotherapy of schizophrenia
by: E. E. Vaiman, et al.
Published: (2019-12-01)

Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations
by: Jungjin Kim, et al.
Published: (2014-04-01)

Olanzapine induced tardive dyskinesia
by: Rudraprosad Chakraborty, et al.
Published: (2014-01-01)

Rhabdomyolysis Related to Dyskinesia in Parkinson’s Disease
by: Hesna Bektaş, et al.
Published: (2014-04-01)

Extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate
by: Francois-Pierre Joubert, et al.
Published: (2021-01-01)

Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function
by: Maryka Quik, et al.
Published: (2013-02-01)

Predictors of levo-dopa induced dyskinesias in Parkinson's disease
by: R T Athulya, et al.
Published: (2020-01-01)

Experimental treatment of antipsychotic-induced movement disorders
by: Shireen E
Published: (2016-08-01)

Valbenazine: Drug review
by: Mahanjit Konwar, et al.
Published: (2017-01-01)

Comparison of the clinical response of stereotactic ventrointermedial thalamotomy with anatomical and pathophysiological features of parkinson's disease
by: VI. Tsymbaliuk, et al.
Published: (2017-12-01)

Management of drug-induced movement disorders in psychiatry: an update
by: Sekh Afrar Alam, et al.
Published: (2016-07-01)

Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
by: Isabel Espadas, et al.
Published: (2020-07-01)

Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson’s disease
by: Sora Ahn, et al.
Published: (2017-04-01)

The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation
by: Eunju Shin, et al.
Published: (2014-02-01)

Parkinsonism and Belly Dancer Syndrome in a Patient with Schizophrenia
by: Luiz Felipe Vasconcellos, et al.
Published: (2019-07-01)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease
by: Sharma VD, et al.
Published: (2018-04-01)

Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia
by: Joanna García, et al.
Published: (2011-09-01)

Tardive dyskinesia: Prevention and newer management strategies
by: Sreelakshmi Vaidyanathan, et al.
Published: (2020-01-01)

Tardive Dyskinesia and Treatment Approaches
by: Mehmet Emin Demirkol, et al.
Published: (2018-06-01)

Clinical and familial correlates of tardive dyskinesia in India and Israel
by: Bhatia T, et al.
Published: (2004-07-01)

Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model
by: Hye-Yeon Park, et al.
Published: (2016-05-01)

Corrigendum: Advances in non-dopaminergic pharmacological treatments of Parkinson’s disease
by: Sandy eStayte, et al.
Published: (2014-08-01)

Serotonin- and Dopamine-mediated Neurotransmission in the Pathophysiology and Treatment of Parkinson’s Disease
by: Huot, Philippe
Published: (2012)